Capital Advisors Inc. OK Raises Stock Position in Medtronic PLC $MDT

Key Points

• Capital Advisors Inc. OK increased its Medtronic position by 16.7% in the second quarter, acquiring 106,104 additional shares and bringing its holdings to 739,685 shares valued at approximately $57.9 million. Institutional investors collectively own 82.06% of Medtronic.
• Medtronic has a “Moderate Buy” consensus rating from analysts, with an average price target of $99.79; Needham recently raised its target to $114 and expects the company to potentially beat first-quarter estimates and raise fiscal 2027 guidance.
• The company reported quarterly revenue of $9.81 billion and adjusted EPS of $1.55, while paying a quarterly dividend of $0.72, equivalent to a 3.2% yield. Investors remain focused on upcoming earnings, with tariff exposure and currency movements posing potential risks.

Capital Advisors Inc. OK raised its position in Medtronic PLC (NYSE:MDT - Free Report) by 16.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 739,685 shares of the medical technology company's stock after purchasing an additional 106,104 shares during the quarter. Capital Advisors Inc. OK owned about 0.06% of Medtronic worth $57,866,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MDT. Brighton Jones LLC lifted its stake in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company's stock worth $380,000 after purchasing an additional 381 shares during the period. Jump Financial LLC acquired a new stake in shares of Medtronic during the 2nd quarter worth about $299,000. Main Street Financial Solutions LLC increased its position in shares of Medtronic by 28.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company's stock worth $1,251,000 after purchasing an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in shares of Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company's stock worth $1,676,000 after purchasing an additional 3,376 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Wall Street Analyst Weigh In

A number of research analysts have commented on MDT shares. Sanford C. Bernstein decreased their target price on shares of Medtronic from $112.00 to $97.00 and set an "outperform" rating on the stock in a research report on Thursday, June 4th. The Goldman Sachs Group dropped their price target on shares of Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research report on Thursday, June 4th. Jefferies Financial Group reissued a "hold" rating and issued a $88.00 price target on shares of Medtronic in a research note on Thursday, June 4th. BTIG Research restated a "buy" rating and issued a $91.00 price objective on shares of Medtronic in a report on Tuesday, August 18th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $118.00 price objective on shares of Medtronic in a report on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $99.79.

Medtronic Price Performance

MDT opened at $91.28 on Friday. The stock's 50-day moving average price is $85.57 and its 200 day moving average price is $85.67. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The firm has a market cap of $116.84 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 2.45 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic's revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. Medtronic's dividend payout ratio (DPR) is presently 77.21%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.27% of the company's stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source